Anticoagulation UK

02 August 2019

The National Institute for Health and Care Excellence (NICE) is recommending Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease

People with chronic coronary artery disease or symptomatic peripheral artery disease can have atherothrombotic events such as myocardial infarction and stroke.

Rivaroxaban plus aspirin is recommended within its marketing authorisation, as an option for preventing atherothrombotic events in adults with coronary artery disease or symptomatic peripheral artery disease who are at high risk of ischaemic events.

For further information go to: https://www.nice.org.uk/guidance/indevelopment/gid-ta10347/documents

Download our fact sheet on Rivaroxaban at:https://www.anticoagulationuk.org/admin/resources/downloads/rivaroxaban-factsheet.pdf